Venezuela Post-Market Surveillance 2026: System Documentation under SACS Review
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
At the registration stage, or afterwards, Venezuela may require the manufacturer or license holder to produce the procedural documentation of its after-sales service and adverse event monitoring system, as evidence of the capability to collect, evaluate and report adverse events and to implement a recall where necessary.
The conclusion is this: this type of system documentation has to be producible at the registration stage or immediately after it, and drafting it at short notice is not a viable route. The reason is that system documentation has value only as evidence that a capability already exists, whereas documentation written to order proves only that a document exists. Against a background of unannounced inspections (article 44 of this series), the difference is identified directly, because file properties, record dates and the absence of populated logs tell the story on their own.
The practical implication is sequencing. The system has to be running before the documents that describe it are written, so that the records inside those documents are genuine. A manufacturer that writes the procedure first and intends to operate it later will produce a document with no records, which is the single most common reason such a submission is rejected as incomplete.
The same logic applies to the after-sales service component, which is often treated as a commercial matter. Service activity generates the field information on which surveillance depends: installation and maintenance records, complaints raised during servicing, and observations made by technicians who see the device in use. If that information stays in a service database that the regulatory system never reads, the surveillance system is described in the file but not fed in practice, and the gap becomes visible as soon as a reviewer asks which service records were evaluated during the reporting period.
2. Legal basis
| Instrument | Number | Publication date | Provisions |
|---|---|---|---|
| Reglamento Orgánico del MPPS | Gaceta Oficial N° 38.591 | December 26, 2006 | Establishment of the inspection and technovigilance department |
| Circular N° DGSACS-008/2026 | DGSACS-008/2026 | July 9, 2026 | Reduction of health risk and safeguarding of traceability |
| Ley Orgánica de Salud (health organization law) | Gaceta Oficial N° 36.579 | November 11, 1998 | Legal basis for the regulation of health products |
Position statement: the possibility that system documentation may be requested at the registration stage or afterwards derives from industry descriptions and is marked as a practical estimate.
The three instruments do not prescribe a document format. What they establish is the institutional expectation: an inspection and technovigilance department exists to examine such systems, and the 2026 circular sets the policy objectives of risk reduction and traceability against which a system is judged. In the absence of a prescribed template, the manufacturer’s own documentation framework carries the burden of proof, and the reviewer is assessing credibility rather than compliance with a checklist.
3. Expert insights
1. Documentation and system are two different things, but an inspection can only see the documentation. A sound system that is not documented is invisible during an inspection; a documented system that is not operated is detected during an inspection, through blank records or contradictory timestamps. The correct approach is to run the system first and let the documents follow, so that what the records contain is real. This ordering also produces better documents, because the procedure is written by people describing what they already do rather than what they intend to do.
2. The core of system documentation is the closed loop, not completeness. Documentation that will be accepted has to show the full loop: how an event is collected, how it is evaluated and classified, how the decision to report or recall is taken, how the action is executed, how effectiveness is verified, and how all of it is recorded. Documentation missing any single step is identified as incomplete, and documentation that contains every step but leaves them disconnected is equally unacceptable. The test is whether a reader can trace one case from notification to closure using only the document.
3. The local interface is the critical chapter. Because execution rests with the license holder (article 45 of this series), the system documentation must define the local arrangement: who receives local information, within what period it is transmitted to the manufacturer, and who reports to SACS. The absence of this chapter is the typical defect in a foreign manufacturer’s documentation, because global system documents are written to cover a portfolio and therefore do not describe country-specific interfaces. A global procedure that is silent on Venezuela reads as an omission rather than as an oversight.
4. System documentation should align with international standards while remaining localized. Industry sources indicate that such systems should conform to internationally recognized standards and be able to interface with the requirements of the Venezuelan health authority. The practical route is to use the manufacturer’s existing system, compliant with standards such as the feedback and adverse event reporting processes of ISO 13485, as the base, and to add a Venezuela-specific chapter on reporting routes and allocation of responsibility. This preserves the audit trail of a mature system while making the local obligations explicit.
4. Practical recommendations
- Regulatory affairs leads: complete the system documentation before the registration application is filed, and make sure it reflects processes that have already been running for some time.
- Quality teams: add a dedicated Venezuela local interface chapter defining responsible persons, transmission deadlines and reporting routes.
- Quality teams: maintain documents and records together, so that every process has records and the timestamps within them are internally consistent.
- License holders: incorporate the system documentation into the renewal file as evidence of continuing compliance (article 41 of this series).
- Manufacturers: align the documented local arrangement with the license holder’s actual capability, so that what the file promises is what the agreement requires.
5. Verification checklist
- □ System documentation was completed before the registration application was filed
- □ The documentation shows a complete loop (collection, evaluation, decision, execution, verification, record)
- □ A Venezuela local interface chapter exists and names responsible persons and deadlines
- □ Processes and records are maintained together with consistent timestamps
- □ Document content matches the terms of the license holder agreement
Regulatory information verified as of October 29, 2026
All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.
— GRZAN Regulatory Team
GRZAN supports medical device and IVD manufacturers, importers and authorized representatives with registration and post-market compliance in Venezuela: dossier preparation and filing through the SACS and COMEX channels, license-holder coordination, technovigilance and adverse event workflows, recall and field corrective action planning, inspection readiness, and continuous monitoring of circulares and decrees. For tailored support on your Venezuela portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us